This website uses cookies to ensure you get the best experience on our website.
Privacy Policy
I Agree
UroToday
Contact
Login
Sign Up Free
Transformative Evidence
mCRPC
CARD Trial
VISION Trial
mHSPC
ARASENS Trial
nmCRPC
ARAMIS Trial
PSMA PET Imaging
CONDOR Trial
OSPREY Trial
Bladder Cancer
Bladder Cancer Detection
Advanced Bladder Cancer
JAVELIN Bladder 100 Trial
Centers of Excellence
Urologic Oncology
Left Group
Bladder Cancer
Bladder Cancer
Ashish Kamat, MD
Advanced Bladder Cancer
Petros Grivas, MD
Kidney Cancer
Advanced Kidney Cancer
Pedro Barata, MD, MSc
Kidney Cancer Today
Sumanta (Monty) Kumar Pal, MD
Jaime Landman, MD
Prostate Cancer
Advanced Prostate Cancer
Alicia Morgans, MD, MPH
CRPC with Bone Metastases
Rana R. McKay, MD
Imaging Center
Phillip Koo, MD
Localized Prostate Cancer
Matthew R. Cooperberg, MD, MPH
mHSPC
Alicia Morgans, MD, MPH
nmCRPC
Alicia Morgans, MD, MPH
PSMA-Targeted Therapy
Upper Tract Urothelial Carcinoma
Upper Tract Urothelial Carcinoma
Sam S. Chang, MD, MBA
TESTICULAR, PENILE & RARE GU MALIGNANCIES
Testicular, Penile, and Rare GU Malignancies
Pelvic Health & Reconstruction
Bladder Health
Diane K. Newman, DNP, ANP-BC, FAAN
Society of Urodynamics, Female Pelvic Medicine & Urogenital Reconstruction (SUFU)
Stephen R. Kraus, MD
Urologic Catheters (Includes CAUTI)
Diane K. Newman, DNP, ANP-BC, FAAN
Videos
Exclusives
Conferences
Exclusive Collaborations
Independent Education
Covid-19
Urologic Oncology
Prostate Cancer
nmCRPC
Bladder Cancer
Kidney Cancer
Upper Tract Urothelial Tumors
Pelvic Health & Reconstruction
Endourology
Testicular Cancer
Clinical Trials
From the Editor
Search Clinical Trials
Transformative Trials
DORA - PCCTC
IRONMAN - PCCTC
PROMISE - PCCTC
SPLASH Trial
Articles
Urology (benign and malignant)
Urologic Oncology
Men's Health
Endourology & Stones
Pediatric Urology
COVID-19 and Genitourinary Cancers
Pelvic Health
Pelvic Health & Reconstruction
Conference Coverage
Recent Conferences
AUA 2022
ASCO 2022
Upcoming
EAU 2022
See All
See All Conference Coverage
PCF
UroToday Home
Recent Abstracts
Urologic Oncology
Bladder Cancer
Conferences
Recent Abstracts
ASCO 2022: Targeting B7-H3 in Prostate Cancer: Phase 2 Trial in Localized Prostate Cancer Using the Anti-B7-H3 Antibody Enoblituzumab, with Biomarker Correlatives
June 6, 2022
ASCO 2022: Tolerability of Abiraterone Combined with Olaparib in Patients with mCRPC: Further Results from the Phase III PROpel Trial
June 6, 2022
ASCO 2022: Influence of Darolutamide on Cabazitaxel Systemic Exposure
June 6, 2022
ASCO 2022: Health-Related Quality of Life and Pain in the MAGNITUDE Study of Niraparib With Abiraterone Acetate and Prednisone in Patients With Metastatic Castration-Resistant Prostate Cancer and HRR Gene Alterations
June 6, 2022
ASCO 2022: Tolerability of [177Lu]Lu-PSMA-617 By Treatment Exposure in Patients With Metastatic Castration-Resistant Prostate Cancer: A VISION Study Subgroup Analysis
June 6, 2022
ASCO 2022: Phase 1 Study of JNJ-69086420, An Actinium-225-Labeled Antibody Targeting Human Kallikrein-2, for Advanced Prostate Cancer
June 6, 2022
ASCO 2022: Overall Survival and Biomarker Results From Combat: A Phase 2 Study of Bipolar Androgen Therapy Plus Nivolumab for Patients With Metastatic Castrate-Resistant Prostate Cancer
June 6, 2022
ASCO 2022: DASL-HiCaP: Darolutamide Augments Standard Therapy for Localized Very High-Risk Cancer of the Prostate (ANZUP1801)—A Randomized Phase 3, Double-Blind, Placebo-Controlled Trial of Adding Darolutamide to ADT and Definitive
June 6, 2022
ASCO 2022: Disparities in Delayed Diagnosis, Access to Treatment, and Treatment Delays Among Hispanic Men With Metastatic Prostate Cancer
June 6, 2022
ASCO 2022: Access to Definitive Treatment and Survival for Intermediate-Risk and High-Risk Prostate Cancer at Hospital Systems Serving Health Disparity Populations
June 6, 2022
ASCO 2022: Impact of PSMA PET/CT on Prostate Cancer Salvage Radiotherapy Management: Results from the Prospective Randomized Phase 3 Trial PSMA SRT
June 6, 2022
ASCO 2022: Genomic Aberrations Associated with Overall Survival in mCSPC Treated with Apalutamide or Placebo + ADT in TITAN
June 6, 2022
ASCO 2022: Feasibility of a Novel Wrist-Worn Thermal Device for Management of Vasomotor Symptoms in Patients with Prostate Cancer
June 6, 2022
ASCO 2022: Clinical Outcomes and Safety of Enzalutamide + ADT in mHSPC in Patients Aged 75 and ≥ 75 Years: ARCHES Post Hoc Analysis
June 6, 2022
ASCO 2022: Association of RB1 Mutational Status With Overall Genomic Landscape in Neuroendocrine Prostate Cancer
June 6, 2022
ASCO 2022: Association of PSA Response and Overall Survival in Patients with mHSPC from the Phase 3 ARASENS Trial
June 6, 2022
ASCO 2022: Outcome of Patients With PSMA PET/CT Screen Failure by VISION Criteria and Treated With 177Lu-PSMA Therapy: A Multicenter Retrospective Analysis
June 6, 2022
ASCO 2022: Circulating Tumour Cells and PSMA PET Correlates in the Phase I PRINCE Trial of 177Lu-PSMA-617 Plus Pembrolizumab for Metastatic Castration Resistant Prostate Cancer
June 6, 2022
ASCO 2022: A Phase III Double Blinded Study of Early Intervention After Radical Prostatectomy with ADT with Darolutamide Versus Placebo in Men at Highest Risk of Prostate Cancer Metastasis by Genomic Stratification (ERADICATE)
June 6, 2022
ANZUP's ENZAMET & TheraP Updated Trial Results Presented at ASCO 2022
June 6, 2022
Page 3 of 472
Start
Prev
1
2
3
4
5
6
7
8
9
10
Next
End
×
Login
Login to update email address, newsletter preferences and use bookmarks.
Email
Password
Login
Forgot Password?
Sign Up Free